China’s NMPA Considers Breakthrough Designations for Xiangxue and Innostellar’s Therapies
Xiangxue Pharmaceutical Co., Ltd (SHE: 300147) and Innostellar Biotherapeutics Co., Ltd have both been noted...
Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy
Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...
Johnson & Johnson Pursues FDA Approval for Spravato as Monotherapy for Treatment-Resistant Depression
Johnson & Johnson (J&J, NYSE: JNJ), a leading global healthcare company, is pursuing expanded approval...
WuXi AppTec Spends Over USD 360,000 on US Lobbying Amid Biosecure Act Deliberations
Endpoints News has reported that WuXi AppTec Co., Ltd, (SHA: 603259) a China-based Contract Development...
Sino Biopharm’s Subsidiary invoX Restructures, Focusing on CD137/PD-L1 Molecule FS222
UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021,...
China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics
Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a...
RemeGen’s Telitacicept Earns Full NMPA Approval for RA Treatment and PMN Clinical Study Green Light
RemeGen (HKG: 9995), a biopharmaceutical company based in China, has announced that the National Medical...
NMPA Suspends Import and Sale of SAMO S.p.A Knee and Hip Prosthesis Systems
The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...
Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary...
Shanghai Medicilon and Jiangsu Hengrui Join Forces to Advance Pre-Clinical Drug Evaluation
Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...
AccurEdit Therapeutics Receives CDE Approval for Gene Editing Drug ART001 Targeting Amyloidosis
AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading specialist in gene editing therapies based in China,...
Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
ICER Analysis Flags Pfizer’s ATTR-CM Therapy Vyndamax/Vyndaqel as Costly, Suggests Price Cut
The Institute for Clinical and Economic Review (ICER), a US-based non-profit organization specializing in drug...
Beijing Launches Bio-Park: A New Hub for International Pharmaceutical Innovation
Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park...
MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...
China’s NMPA and NHC Implement New Rules for Temporary Import of Urgent Medical Devices
The National Medical Products Administration (NMPA) and the National Health Commission have issued the Management...
Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered...
Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...
China Unveils Ambitious Healthcare Reforms at 20th Central Committee Plenary Session
The third plenary session of the 20th Central Committee of the Communist Party of China...
Jiangsu Hengrui Receives NMPA Approval to Study CDK 4/6 Inhibitor Dalpiciclib in Combination with HRS-1358 for Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has received...